Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Analysts at Raymond James issued their Q3 2025 earnings estimates for Medexus Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 19th. Raymond James analyst M. Freeman expects that the company will post earnings per share of $0.01 for the quarter. Raymond James has a "Outperform" rating and a $4.00 price target on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals' Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $0.90 EPS and FY2028 earnings at $0.89 EPS.
Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus increased their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a "buy" rating in a research report on Thursday, August 22nd. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the stock a "speculative buy" rating in a research note on Monday, September 30th. Finally, Stifel Canada raised Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Monday, August 12th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of C$5.25.
Check Out Our Latest Stock Analysis on MDP
Medexus Pharmaceuticals Stock Performance
Shares of TSE:MDP traded up C$0.32 during mid-day trading on Friday, reaching C$2.45. 46,306 shares of the company's stock were exchanged, compared to its average volume of 41,558. The firm has a market capitalization of C$60.10 million, a price-to-earnings ratio of 42.60 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.44 and a twelve month high of C$3.16. The business's fifty day moving average price is C$2.46 and its 200-day moving average price is C$2.19.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
